Revvity, Inc. (NYSE: RVTY) announced that it will acquire ACD/Labs, a global provider of analytical chemistry and molecular design software, for an estimated $70 million in cash. The definitive agreement, signed on November 10 2025, is expected to close in the fourth quarter of 2025 and will add ACD/Labs’ deep expertise in analytical and process chemistry to Revvity’s Signals software franchise.
Continue reading for full analysis...